Diluent A195 clinical trials

A 26-Week (with 26 Week Extension) Randomized, Multi-Center, Double-Blind Phase 2 Study to Evaluate the Efficacy and Safety of XC001 Gene Therapy as an Adjunct to Coronary Artery Bypass Graft Surgery for Patients with Symptomatic Coronary Artery Disease with Left Ventricular Dysfunction at Risk for Incomplete Revascularization

This study looks into a new gene therapy, XC001, for people with severe heart disease who've had bypass surgery. It aims to see if XC001 can help improve heart function and reduce chest pain more than a dummy treatment.